BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17849424)

  • 1. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Vaninetti NM; Geldenhuys L; Porter GA; Risch H; Hainaut P; Guernsey DL; Casson AG
    Mol Carcinog; 2008 Apr; 47(4):275-85. PubMed ID: 17849424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary folate and vitamin B6 are not associated with p53 mutations in esophageal adenocarcinoma.
    Balbuena L; Casson AG
    Mol Carcinog; 2010 Mar; 49(3):211-4. PubMed ID: 20025073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
    Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran.
    Biramijamal F; Allameh A; Mirbod P; Groene HJ; Koomagi R; Hollstein M
    Cancer Res; 2001 Apr; 61(7):3119-23. PubMed ID: 11306496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
    Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
    J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Carcinogenesis of Barrett's esophagus].
    Endo T; Sugawara N; Shinomura Y
    Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.
    Casson AG; Zheng Z; Evans SC; Veugelers PJ; Porter GA; Guernsey DL
    Carcinogenesis; 2005 Sep; 26(9):1536-41. PubMed ID: 15878910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
    Chung SM; Kao J; Hyjek E; Chen YT
    Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
    Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran.
    Sepehr A; Tanière P; Martel-Planche G; Zia'ee AA; Rastgar-Jazii F; Yazdanbod M; Etemad-Moghadam G; Kamangar F; Saidi F; Hainaut P
    Oncogene; 2001 Nov; 20(50):7368-74. PubMed ID: 11704866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.